CytoSen is a clinic ready biotechnology company seeking to advance Natural Killer (NK) cell therapies for oncology indications with high unmet medical need. CytoSen has developed a proprietary nanoparticle platform that demonstrates robust expansion of tumor killing NK cells, enabling repeat administration of higher doses of cells over longer periods of time. CytoSen’s nanoparticle technology represents a safer more effective solution for NK cell expansion that can unlock potential to treat thousands of cancer patients.
Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. By developing innovative products that address the processes that are necessary for the study of immuno-oncology we help researchers advance science in these key areas as well as help clinicians to make the concept of cellular therapy a reality.
Irvine Scientific, a member of JXTG Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and…
Since our start in 2006, research and development efforts at Akron Biotech have led to discoveries that have fuelled the development of some of the most innovative products to support cell and gene therapy research, clinical development and commercialization. Now, Akron operates from a 14,000 sf facility in Boca Raton as a leader in innovation and cGMP manufacturing.
BioSpherix will be exhibiting the Xvivo System, the only total quality platform for cells. Economical alternative to cleanrooms for cGMP compliant production of cells. Total quality recognizes that cells need full-time optimization of all critical process parameters. All typical negative side effects of machines on cells must be neutralized. Total quality recognizes that all personnel must be fully protected …
CTL specializes in cellular immune monitoring, and was the first entity to validate ELISPOT assays for clinical trials, also patenting the first automated ELISPOT analyzer. CTL’s NK-TVA platform is an extension of our immune monitoring efforts, and provides an image cytometry platform for measuring NK cell cytolytic activity, as well as ADCC, and CD8 T cell cytotoxicity. NK-TVA is a high-throughput, non-radioactive alternative to traditional 51Cr-release assays, using direct, fluorescence-based cell imaging.Li
Universal Cells creates Universal Donor Stem Cells by editing the genes required for immune recognition. By using our recombinant Adeno-Associated Virus (rAAV) technology, we design and manufacture stem cell-based products that can be used as off-the-shelf cell therapies.